Molecular Epidemiology of Non-Small Cell Lung Cancer (original) (raw)

Semin Respir Crit Care Med 2005; 26(3): 265-272
DOI: 10.1055/s-2005-871983

Geoffrey Liu1 , 2 , 3 , Wei Zhou2 , David C. Christiani1 , 2 , 3

1Harvard Medical School, Boston, Massachusetts
2Harvard School of Public Health, Boston, Massachusetts
3Massachusetts General Hospital Cancer Center, Boston, Massachusetts

Further Information

Publication History

Publication Date:
29 June 2005 (online)

ABSTRACT

Although smoking is the primary risk factor for most lung cancers, genetic predisposition may play an important role. Familial aggregation studies suggest a greater genetic component in the risk for younger individuals developing lung cancer, for lifetime nonsmokers, and possibly for women. Low-penetrance, high-prevalence polymorphic genes may explain part of this genetic predisposition. Functional polymorphisms of xenobiotic metabolism may alter the total exposure of tobacco carcinogens in the host. Subtle alterations in the DNA repair, inflammatory, and cell cycle pathways may also alter lung cancer susceptibility. The role of individual polymorphisms has been evaluated for several genes including the CYP and glutathione s-transferase superfamilies, and the NAT genes; DNA repair genes such as XPD (nucleotide excision pathway), XRCC1 (base excision pathway), and MGMT; and tumor suppressor or cell cycle genes such as p53. Molecular epidemiological studies are now focused on building larger databases from existing smaller studies and developing strategies to simultaneously evaluate multiple polymorphisms and genes within the same pathway.

KEYWORDS

Molecular epidemiology - polymorphism - genetic susceptibility - lung cancer

REFERENCES

1 American Cancer Society .Tobacco use. In: American Cancer Society, Cancer Facts & Figures 2001 Atlanta, GA; American Cancer Society 2001: 29-32
2 Smith-Warner S A, Spiegelman D, Yaun S S et al.. Fruits, vegetables and lung cancer: a pooled analysis of cohort studies. Int J Cancer. 2003; 107 1001-1011
3 Fabricius P, Lange P. Diet and lung cancer. Monaldi Arch Chest Dis. 2004; 59 207-211
4 Miller A B, Altenburg H P, Bueno-de-Mesquita B et al.. Fruits and vegetables and lung cancer: findings from the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2004; 108 269-276
5 Christiani D C. Utilization of biomarker data for clinical and environmental intervention. Environ Health Perspect. 1996; 104(Suppl 5) 921-925
6 Wu X, Zhao H, Suk R, Christiani D C. Genetic susceptibility to tobacco-related cancer. Oncogene. 2004; 23 6500-6523
7 Rottman H. Uber primare Lungencarcinoma. Inaugural dissertation. Universitat Wurzburg 1898
8 Adler I. Primary Malignant Growths of the Lung and Bronchi. London; Longmans Green & Co 1912
9 Wynder E L, Graham E A. Tobacco smoking as a possible etiologic factor in bronchogenic carcinoma. JAMA. 1950; 143 329-336
10 Doll R, Hill A B. Smoking and carcinoma of the lung; preliminary report. BMJ. 1950; 2 739-748
11 US Department of Health and Human Services .The Health Consequences of Smoking: A Report of the Surgeon General. http://www.hhs.gov/surgeongeneral/library/smokingconsequences/
12 Hecht S S. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst. 1999; 91 1194-1210
13 Miller C W, Simon K, Aslo A et al.. p53 mutations in human lung tumors. Cancer Res. 1992; 52 1695-1698
14 Law M R. Genetic predisposition to lung cancer. Br J Cancer. 1990; 61 195-206
15 Hoffmann D, Hecht S S. Nicotine-derived N-nitrosamines and tobacco-related cancer: current status and future directions. Cancer Res. 1985; 45 935-944
16 Lambert W C, Kuo H R, Lambert M W. Xeroderma pigmentosum. Dermatol Clin. 1995; 13 169-209
17 Kuper H, Adami H O, Boffetta P. Tobacco use, cancer causation and public health impact. J Intern Med. 2002; 251 455-466
18 Tokuhata G K, Lilienfeld A M. Familial aggregation of lung cancer in humans. J Natl Cancer Inst. 1963; 30 289-312
19 Ooi W L, Elston R C, Chen V W, Bailey-Wilson J E, Rothschild H. Increased familial risk for lung cancer. J Natl Cancer Inst. 1986; 76 217-222
20 Sellers T A, Ooi W L, Elston R C, Chen V W, Bailey-Wilson J E, Rothschild H. Increased familial risk for non-lung cancer among relatives of lung cancer patients. Am J Epidemiol. 1987; 126 237-246
21 Sellers T A, Elston R C, Stewart C, Rothschild H. Familial risk of cancer among randomly selected cancer probands. Genet Epidemiol. 1988; 5 381-391
22 Shaw G L, Falk R T, Pickle L W, Mason T J, Buffler P A. Lung cancer risk associated with cancer in relatives. J Clin Epidemiol. 1991; 44 429-437
23 Knudson Jr A G. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971; 68 820-823
24 Sellers T A, Bailey-Wilson J E, Elston R C et al.. Evidence for mendelian inheritance in the pathogenesis of lung cancer. J Natl Cancer Inst. 1990; 82 1272-1279
25 Schwartz A G, Yang P, Swanson G M. Familial risk of lung cancer among nonsmokers and their relatives. Am J Epidemiol. 1996; 144 554-562
26 Mayne S T, Buenconsejo J, Janerich D T. Familial cancer history and lung cancer risk in United States nonsmoking men and women. Cancer Epidemiol Biomarkers Prev. 1999; 8 1065-1069
27 Bailey-Wilson J E, Amos C I, Pinney S M et al.. A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am J Hum Genet. 2004; 75 460-474
28 Thorisson G A, Stein L D. The SNP Consortium website: past, present and future. Nucleic Acids Res. 2003; 31 124-127
29 Benhamou S, Lee W J, Alexandrie A K et al.. Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. Carcinogenesis. 2002; 23 1343-1350
30 Rutter J L, Mitchell T I, Buttice G et al.. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res. 1998; 58 5321-5325
31 Rutter J L, Mitchell T I, Buttice G et al.. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res. 1998; 58 5321-5325
32 Yagil Y, Yagil C. Candidate genes, association studies and haplotype analysis in the search for the genetic basis of hypertension. J Hypertens. 2004; 22 1255-1258
33 Wiencke J K, Kelsey K T, Varkonyi A et al.. Correlation of DNA adducts in blood mononuclear cells with tobacco carcinogen-induced damage in human lung. Cancer Res. 1995; 55 4910-4914
34 Wogan G N, Gorelick N J. Chemical and biochemical dosimetry of exposure to genotoxic chemicals. Environ Health Perspect. 1985; 62 5-18
35 Bartsch H, Nair U, Risch A, Rojas M, Wikman H, Alexandrov K. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev. 2000; 9 3-28
36 Reszka E, Wasowicz W. Significance of genetic polymorphisms in glutathione S-transferase multigene family and lung cancer risk. Int J Occup Med Environ Health. 2001; 14 99-113
37 Gelboin H V. Benzo[alpha]pyrene metabolism, activation and carcinogenesis: role and regulation of mixed-function oxidases and related enzymes. Physiol Rev. 1980; 60 1107-1166
38 Hein D W, Doll M A, Rustan T D, Ferguson R J. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res. 1995; 55 3531-3536
39 Lee W J, Brennan P, Boffetta P et al.. Microsomal epoxide hydrolase polymorphisms and lung cancer risk: a quantitative review. Biomarkers. 2002; 7 230-241
40 Williams J A. Single nucleotide polymorphisms, metabolic activation and environmental carcinogenesis: why molecular epidemiologists should think about enzyme expression. Carcinogenesis. 2001; 22 209-214
41 Kiyohara C, Otsu A, Shirakawa T, Fukuda S, Hopkin J M. Genetic polymorphisms and lung cancer susceptibility: a review. Lung Cancer. 2002; 37 241-256
42 Williams M D, Sandler A B. The epidemiology of lung cancer. Cancer Treat Res. 2001; 105 31-52
43 Hirvonen A. Polymorphic NATs and cancer predisposition. IARC Sci Publ. 1999; 148 251-270
44 Matakidou A, Eisen T, Houlston R S. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis. 2003; 18 377-385
45 Feyler A, Voho A, Bouchardy C et al.. Point: myeloperoxidase-463G: a polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2002; 11 1550-1554
46 Zhou W, Liu G, Thurston S W et al.. Genetic polymorphisms in N-acetyltransferase-2 and microsomal epoxide hydrolase, cumulative cigarette smoking, and lung cancer. Cancer Epidemiol Biomarkers Prev. 2002; 11 15-21
47 Berwick M, Vineis P. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst. 2000; 92 874-897
48 Wei Q, Cheng L, Amos C I et al.. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst. 2000; 92 1764-1772
49 Duell E J, Wiencke J K, Cheng T J et al.. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis. 2000; 21 965-971
50 Ratnasinghe D, Yao S X, Tangrea J A et al.. Polymorphisms of the DNA repair gene XRCC1 and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2001; 10 119-123
51 Chen S, Tang D, Xue K et al.. DNA repair gene XRCC1 and XPD polymorphisms and risk of lung cancer in a Chinese population. Carcinogenesis. 2002; 23 1321-1325
52 Park J Y, Lee S Y, Jeon H S et al.. Polymorphism of the DNA repair gene XRCC1 and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev. 2002; 11 23-27
53 David-Beabes G L, London S J. Genetic polymorphism of XRCC1 and lung cancer risk among African-Americans and Caucasians. Lung Cancer. 2001; 34 333-339
54 Misra R R, Ratnasinghe D, Tangrea J A et al.. Polymorphisms in the DNA repair genes XPD, XRCC1, XRCC3, and APE/ref-1, and the risk of lung cancer among male smokers in Finland. Cancer Lett. 2003; 191 171-178
55 Hung R J, Brennan P, Canzian F et al.. Large-scale investigation of base excision repair genetic polymorphisms and lung cancer risk in a multicenter study. J Natl Cancer Inst. 2005; 97 567-576
56 Zhou W, Liu G, Miller D P et al.. Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2003; 12 359-365
57 Benhamou S, Sarasin A. ERCC2/XPD gene polymorphisms and lung cancer: a HuGE review. Am J Epidemiol. 2005; 161 1-14
58 Johnson E S. Nested case-control study of lung cancer in the meat industry. J Natl Cancer Inst. 1991; 83 1337-1339
59 Zhou W, Liu G, Park S et al.. Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer. Cancer Epidemiol Biomarkers Prev. 2005; 14 491-496
60 Wu X, Zhao H, Wei Q et al.. XPA polymorphism associated with reduced lung cancer risk and a modulating effect on nucleotide excision repair capacity. Carcinogenesis. 2003; 24 505-509
61 Butkiewicz D, Popanda O, Risch A et al.. Association between the risk for lung adenocarcinoma and a (-4) G-to-A polymorphism in the XPA gene. Cancer Epidemiol Biomarkers Prev. 2004; 13 2242-2246
62 Park J Y, Park S H, Choi J E et al.. Polymorphisms of the DNA repair gene xeroderma pigmentosum group A and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev. 2002; 11 993-997
63 Kaur T B, Travaline J M, Gaughan J P et al.. Role of polymorphisms in codons 143 and 160 of the O6-alkylguanine DNA alkyltransferase gene in lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2002; 9 339-342
64 Cohet C, Borel S, Nyberg F et al.. Exon 5 polymorphisms in the O6-alkylguanine DNA alkyltransferase gene and lung cancer risk in nonsmokers exposed to secondhand smoke. Cancer Epidemiol Biomarkers Prev. 2004; 13 320-323
65 Krzesniak M, Butkiewicz D, Samojedny A, Chorazy M, Rusin M. Polymorphisms in TDG and MGMT genes: epidemiological and functional study in lung cancer patients from Poland. Ann Hum Genet. 2004; 68 300-312

Geoffrey LiuM.D.

Harvard Medical School, Harvard School of Public Health

Massachusetts General Hospital Cancer Center, Yawkey 7B, 55 Fruit St.

Boston, MA 02115

Email: gliu1@partners.org